Investigating the role of mitochondrial DNA and TLR9 in lung scarring
Mitochondrial DNA and TLR9 in Pulmonary Fibrosis
This study is looking at how certain parts of our cells might play a role in the lung scarring seen in idiopathic pulmonary fibrosis (IPF), with the hope of finding new ways to improve treatments for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10894850 on NIH RePORTER |
What this research studies
This research focuses on understanding how mitochondrial DNA and Toll-Like Receptor 9 (TLR9) contribute to the development of idiopathic pulmonary fibrosis (IPF), a chronic lung disease characterized by scarring of lung tissue. The project utilizes laboratory-based assays and in vitro models to explore the innate immune responses involved in IPF. By combining expertise in immunology and computational biology, the research aims to uncover new insights into the mechanisms driving fibrosis and potentially identify new therapeutic targets. Patients may benefit from advancements in treatment options based on the findings of this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis, particularly those over 21 years old.
Not a fit: Patients with other forms of lung disease or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients suffering from idiopathic pulmonary fibrosis.
How similar studies have performed: Previous research has shown promising results in understanding the role of innate immunity in pulmonary fibrosis, suggesting that this approach could yield significant insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Ryu, Changwan — Yale University
- Study coordinator: Ryu, Changwan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.